11 January 2021

TauRx announces completion of Phase 3 study enrolment for the first tau-based disease modifying treatment for Alzheimer’s disease

Aberdeen, Scotland and Singapore [January 11, 2021] – TauRx Pharmaceuticals Ltd today announced it has completed patient enrolment of the LUCIDITY study (NCT03446001) ahead of schedule, despite delays due to the COVID-19 pandemic.

TauRx is pleased to be presenting its latest trial results at Biotech Showcase™ 2021 during the J.P. Morgan 39th Annual Healthcare Conference 2021. LUCIDITY is the only late-stage study targeting the tau pathology of Alzheimer’s disease. It aims to confirm hydromethylthionine as the first tau-based disease modifying treatment for Mild Cognitive Impairment and Mild-Moderate AD.

Read more here

More news

MHRA confirms acceptance of UK Marketing Authorisation Application for HMTM

TauRx submits UK marketing authorisation application for HMTM as a treatment for Alzheimer’s disease

Doctor examining MRI, MRT, CT scan image of human brain. Medical treatment concept. Diagnosis of the disease humans head. Close up.

Two year sustained cognitive benefits of Hydromethylthionine Mesylate (HMTM) indicated by TauRx’s LUCIDITY trial

Further reading

For decades, Professor Claude Wischik, co-founder and CEO of TauRx, has led a scientific research team dedicated to finding an effective treatment for neurodegenerative diseases.

Doctor or nurse caregiver with senior couple at home or nursing home

Clinical trials

TauRx recently completed its latest Phase III clinical trials in Alzheimer’s disease and in the rare neurodegenerative disorder, behavioural variant frontotemporal dementia (bvFTD).

Gears. Cog mechanism, engine system, operation progress, gear shift, industry innovation, engineering solution, technology concept.

Environmental, Social and Governance at TauRx

Maintaining integrity, accountability and transparency in our pursuit of life-changing treatments